It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We aimed to identify independent predictors of cardiac mortality and hospitalization for heart failure (HHF) from a real-world, multi-ethnic Asian registry [the Singapore Myocardial Infarction Registry] of ST-segment elevation myocardial infarction (STEMI) patients treated by primary percutaneous coronary intervention. 11,546 eligible STEMI patients between 2008 and 2015 were identified. In-hospital, 30-day and 1-year cardiac mortality and 1-year HHF rates were 6.4%, 6.8%, 8.3% and 5.2%, respectively. From the derivation cohort (70% of patients), age, Killip class and cardiac arrest, creatinine, hemoglobin and troponin on admission and left ventricular ejection fraction (LVEF) during hospitalization were predictors of in-hospital, 30-day and 1-year cardiac mortality. Previous ischemic heart disease (IHD) was a predictor of in-hospital and 30-day cardiac mortality only, whereas diabetes was a predictor of 1-year cardiac mortality only. Age, previous IHD and diabetes, Killip class, creatinine, hemoglobin and troponin on admission, symptom-to-balloon-time and LVEF were predictors of 1-year HHF. The c-statistics were 0.921, 0.901, 0.881, 0.869, respectively. Applying these models to the validation cohort (30% of patients) showed good fit and discrimination (c-statistic 0.922, 0.913, 0.903 and 0.855 respectively; misclassification rate 14.0%, 14.7%, 16.2% and 24.0% respectively). These predictors could be incorporated into specific risk scores to stratify reperfused STEMI patients by their risk level for targeted intervention.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, United Kingdom; Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore; National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore; Norfolk and Norwich University Hospital, Department of Cardiology, Norwich, UK
2 National Registry of Disease Office, Health Promotion Board, Singapore, Singapore
3 National University Heart Centre, Singapore, Singapore
4 Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore; National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore
5 Tan Tock Seng Hospital, Singapore, Singapore
6 Khoo Teck Puat Hospital, Singapore, Singapore
7 Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore
8 Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore; Karolinska Institutet, Department of Cardiology, Stockholm, Sweden
9 Changi General Hospital, Singapore, Singapore
10 The Hatter Cardiovascular Institute, Institute of Cardiovascular Science, University College London, London, United Kingdom; Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore; National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore; Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore; The National Institute of Health Research University College London Hospitals Biomedical Research Centre, Research & Development, London, UK; Tecnologico de Monterrey, Centro de Biotecnologia-FEMSA, Nuevo Leon, Mexico